Increased Bone Formation and Bone Mass Induced by Sclerostin Antibody Is Not Affected by Pretreatment or Cotreatment with Alendronate in Osteopenic, Ovariectomized Rats

Clinical studies have revealed a blunting of the bone anabolic effects of parathyroid hormone treatment in osteoporotic patients in the setting of pre- or cotreatment with the antiresorptive agent alendronate (ALN). Sclerostin monoclonal antibody (Scl-Ab) is currently under clinical investigation as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Endocrinology (Philadelphia) 2011-09, Vol.152 (9), p.3312-3322
Hauptverfasser: Li, Xiaodong, Ominsky, Michael S, Warmington, Kelly S, Niu, Qing-Tian, Asuncion, Franklin J, Barrero, Mauricio, Dwyer, Denise, Grisanti, Mario, Stolina, Marina, Kostenuik, Paul J, Simonet, William S, Paszty, Chris, Ke, Hua Zhu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!